A Phase 2 interventional study of intracochlear triamcinolone acetonide injection and intracochlear injection of dexamethasone through the round window membrane in Sudden Sensorineural Hearing Loss (SSNHL), sponsored by Eye & ENT Hospital of Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by Eye & ENT Hospital of Fudan University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hearing Loss, Sudden with a site in China — 11 open to participants now, 11 under way, 1 of them phase 3. Hearing Loss, Sudden · China.
Among the 18 studies in Hearing Loss, Sudden with a site in China, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 12th registered.
66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.
Browse Hearing Loss, Sudden studies →11 of the 18 studies in Hearing Loss, Sudden with a site in China are open now. Recruiting first, the newest first:
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–70
Guangdong Provincial People's Hospital · Sites in China
Ages 18–60
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–60
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18–70
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–65 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2019; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 72 across 49 interventional studies indexed under Hearing Loss, Sudden.
Median enrollment 90 across the 15 interventional studies, 90 across the 3 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 18 have an industry lead sponsor. The 10 most frequent:
Eye & ENT Hospital of Fudan University is the lead sponsor of 127 studies on the registry; 71 are open to participants now.
Eye & ENT Hospital of Fudan University has 6 studies filed under Hearing Loss, Sudden — fewer than ten, so there is no comparison to draw.
2 of the studies in Hearing Loss, Sudden with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07134075Eye & ENT Hospital of Fudan UniversityIntracochlear Injection of Glucocorticoid | 2027-08-01 |
| NCT07505667Guangdong Provincial People's HospitalYiyuancong for the Treatment of Sudden Sensorineural Hearing Loss | 2027-11-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Hearing Loss, Sudden with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, randomized pilot study. To verify safety and efficacy of intracochlear injection of glucocorticoid through the round window membrane in patients with total sudden sensorineural hearing loss safety and efficacy in total sudden sensorineural hearing loss patients as an early salvage therapy.
The main questions it aims to answer are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age between 18 and 65 years Unilateral idiopathic sudden sensorineural hearing loss greater than 95dB at the average of 4 frequencies (500 Hz, 1000 Hz, 2000 Hz and 4000 Hz) in PTA (contralateral hearing is less than 30dB) at the onset of sudden hearing loss Participant who were treated with standard treatment for 14 days, but no recovery was confirmed as type IV (final hearing level with hearing gain of ≤15 dB) at the end of the 14-day treatment
Exclusion Criteria:
Bilateral sudden sensorineural hearing loss Hearing loss with known causes (e.g., Meniere's disease, retrocochlear pathology, history of otologic surgery, perilymphatic fistula, barotrauma) History in the past 6 months of ototoxic treatment such as chemotherapy, use of loop diuretics, high dose aspirin, etc History of sudden sensorineural hearing loss within the past 2 years History of ischemic diseases (cerebral infarction, myocardial infarction, peripheral arterial obstructive disease) Neuropsychiatric disorders (epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis) Severe hepatic or renal insufficiency The CT diagnosis is "abnormality of the round window niche"
intracochlear injection of triamcinolone acetonide through the round window membrane
Drug: intracochlear triamcinolone acetonide injection
intracochlear injection of dexamethasone through the round window membrane
Drug: intracochlear injection of dexamethasone through the round window membrane
intracochlear injection of dexamethasone through the round window membrane and intratympanic dexamethasone injection through the tympanic membrane
Drug: intracochlear dexamethasone injection and intratympanic dexamethasone injection
intratympanic dexamethasone injection tympanic membrane,once every other day, for a total of 4 injections.
Drug: intratympanic dexamethasone injection
intracochlear triamcinolone acetonide injection of through the round window membrane
Also known as: intracochlear triamcinolone acetonide (40mg/ml, 30μl)injection
intracochlear injection of dexamethasone sodium phosphate through the round window membrane
Also known as: intracochlear injection of dexamethasone sodium phosphate(7.5mg/ml, 30μl)through the round window membrane
intracochlear dexamethasone sodium phosphate injection of through the round window membrane, intratympanic dexamethasone sodium phosphate injection through the tympanic membrane
Also known as: intracochlear injection of dexamethasone sodium phosphate through the round window membrane (7.5mg/ml, 30μl) and intratympanic dexamethasone sodium phosphate injection (10mg/ml)
intratympanic dexamethasone sodium phosphate injection (10mg/ml) through tympanic membrane,once every other day, for a total of 4 injections.
Also known as: intratympanic dexamethasone sodium phosphate injection (10mg/ml)
Change from Baseline in pure tone audiometry (PTA)
hearing capacity of thresholds (PTA)
Time frame: Baseline, Week 2, Week 4, Week12, Week24
Change from Baseline in auditory brainstem response (ABR)
hearing capacity of thresholds (ABR)
Time frame: Baseline, Week 2, Week 4, Week12, Week24
Change from Baseline in auditory steady state response (ASSR)
hearing capacity of thresholds (ASSR)
Time frame: Baseline, Week 2, Week 4, Week12, Week24
Change from Baseline in speech Discrimination Scores
hearing capacity of thresholds (speech Discrimination Scores)
Time frame: Baseline, Week 2, Week 4, Week12, Week24
change from baseline in tinnitus handicap inventory
The THI questionnaire includes functional, emotional, and catastrophic subscales. It consists of 25 questions. The total score is calculated by adding up the scores for all questions and classifying the severity of tinnitus as no handicap (0-16), mild handicap (18-36), moderate handicap (38-56), and severe handicap (58-100).
Time frame: Baseline, Week2, Week4, Week12, Week24
change from baseline in dizziness handicap inventory
The 25-item self-report Dizziness Handicap inventory (DHI) validated questionnaire that assesses functional, emotional and physical domains. Responses are graded 0 (no), 2 (sometimes) or 4 (yes) with higher scores indicating greater impact of dizziness maximum and maximum score of 100 points (15 minutes).
Time frame: Baseline, Week2, Week4, Week12, Week24
change from baseline in quality of life score
Quality of life questionnaire will be measured to compare the change in individual's health-related quality of life using face to face Interview for the scores. Higher scores mean better functioning or fewer symptoms.
Time frame: Baseline, Week2, Week4, Week12, Week24
Plan to share: No — The ethics committee may require approval for data sharing to ensure alignment with principles like beneficence and justice.
Start is estimated for Aug 2025; primary completion for Aug 2027, 23 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eye & ENT Hospital of Fudan University →